This website uses cookies to ensure you get the best experience on our website. Privacy Policy
UroToday UroToday
  • Contact
  • Login
  • Sign Up Free
  • Transformative Evidence
    • mCRPC
      • The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
      • PROfound
      • VISION Trial
    • mHSPC
      • ARASENS Trial
    • nmCRPC
      • ARAMIS Trial
    • PSMA PET Imaging
      • CONDOR Trial
      • OSPREY Trial
    • Bladder Cancer
      • Bladder Cancer Detection
  • Centers of Excellence
    • Urologic Oncology
      • Left Group
        • Bladder Cancer
          • Bladder Cancer
            Ashish Kamat, MD
          • Advanced Bladder Cancer
            Petros Grivas, MD
        • Kidney Cancer
          • Advanced Kidney Cancer
            Pedro Barata, MD, MSc
          • Kidney Cancer Today
            Sumanta (Monty) Kumar Pal, MD
            Jaime Landman, MD
      • Prostate Cancer
        • Advanced Prostate Cancer
          Alicia Morgans, MD, MPH
        • CRPC with Bone Metastases
          Rana R. McKay, MD
        • Imaging Center
          Phillip Koo, MD
        • Localized Prostate Cancer
          Matthew R. Cooperberg, MD, MPH
        • mHSPC
          Alicia Morgans, MD, MPH
        • nmCRPC
          Alicia Morgans, MD, MPH
        • PSMA-Targeted Therapy
      • Translational Prostate Cancer
        • Women in Science
          Andrea Miyahira, Ph.D
        • Health Policy
          Andrea Miyahira, Ph.D
      • Upper Tract Urothelial Carcinoma
        • Upper Tract Urothelial Carcinoma
          Sam S. Chang, MD, MBA
      • TESTICULAR, PENILE & RARE GU MALIGNANCIES
        • Testicular, Penile, and Rare GU Malignancies
    • Pelvic Health & Reconstruction
      • Bladder Health
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
        Stephen R. Kraus, MD
      • Urologic Catheters (Includes CAUTI)
        Diane K. Newman, DNP, ANP-BC, FAAN
  • Videos
    • Exclusives
      • Conferences
      • Exclusive Collaborations
      • Independent Education
      • Covid-19
      • The Prostate Cancer Foundation
    • Urologic Oncology
      • Prostate Cancer
      • Bladder Cancer
      • Kidney Cancer
      • Upper Tract Urothelial Tumors
      • Pelvic Health & Reconstruction
      • Endourology
      • Testicular Cancer
      • Health Policy in Urological Diseases
  • Clinical Trials
    • From the Editor
      • Search Clinical Trials
    • Trials in Progress
      • DORA - PCCTC
      • IRONMAN - PCCTC
      • PROMISE - PCCTC
      • SPLASH Trial
      • Oral EPI-7386
  • Articles
    • Urology (benign and malignant)
      • Urologic Oncology
      • Men's Health
      • Endourology & Stones
      • Pediatric Urology
      • COVID-19 and Genitourinary Cancers
    • Pelvic Health
      • Pelvic Health & Reconstruction
  • Conference Coverage
    • Recent Conferences
      • SUO 2022
      • ASCO GU 2023
      • EAU 2023
    • All Conferences
      • View All
  • PCF
  1. UroToday Home
  2. Video Lectures

ESMO 2021 Videos

Cabazitaxel as a Third-Line Treatment After Docetaxel and an Androgen Receptor Targeting Agent in mCRPC Patients – Alicia Morgans
December 27, 2021
Details
Enzalutamide Plus Talazoparib vs Placebo Plus Enzalutamide in Men With DDR Gene Mutations, the TALAPRO-3 Trial in mCSPC – Neeraj Agarwal
November 29, 2021
Details
Practice-Changing and Emerging Treatment Strategies in Metastatic Urothelial Carcinoma - Guru Sonpavde
November 18, 2021
Details
Preliminary Results of MGC018, an anti B7-H3 Antibody Drug Conjugate in mCRPC – Eugene Shenderov
November 18, 2021
Details
Tazemetostat in Combination With Abiraterone + Prednisone or Enzalutamide in mCRPC – Wassim Abida
November 12, 2021
Details
Cabazitaxel in Male Patients with Chemotherapy Pre-Treated Metastatic Germ-Cell Tumors CABA-GCT - Giulia Baciarello
November 10, 2021
Details
Prospective Analysis of The Effect of Germline Mutations on Outcomes for mCRPC Patients Treated With Radium-223 (PRORADIUM) – Elena Castro
November 9, 2021
Details
CheckMate 9KD Trial CohortA2 Evaluating Nivolumab + Rucaparib for Chemotherapy-Naïve mCRPC - Daniel Petrylak
November 7, 2021
Details
Cisplatin-Related Immunomodulation and Efficacy with Atezolizumab + Cisplatin Versus Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer - Matthew Galsky
November 4, 2021
Details
Sabizabulin in Men with Metastatic Castration Resistant Prostate Cancer - Mark Markowski
October 31, 2021
Details
Time Course Profile of Adverse Events With Darolutamide in the ARAMIS Trial – Christian Gratzke
October 27, 2021
Details
Cognitive Assessment in Men with Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Randomly Receiving Darolutamide or Enzalutamide in the ODENZA Trial - Karim Fizazi
October 16, 2021
Details
Darolutamide Maintenance in mCRPC Previously Treated with Novel Hormonal Agents - Richard Cathomas
October 16, 2021
Details
Therapy Resistance Identified in Circulating Tumor Cell Morphologic Sub-Types Present Prior to Treatment in the CARD Trial - Cora Sternberg
October 15, 2021
Details
Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer – Ravi Madan
October 15, 2021
Details
PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients – Michael Morris
October 15, 2021
Details
First-in-Human Study of FOR46 in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC) – Rahul Aggarwal
October 3, 2021
Details
Pain and Symptomatic Skeletal Events Reported in the VISION Trial – Oliver Sartor
October 3, 2021
Details
Frontline Cabozantinib in Metastatic Collecting Ducts Renal Cell Carcinoma – Giuseppe Procopio
September 28, 2021
Details
Evaluating the Efficacy of Sabizabulin in The Treatment of Metastatic Castration-Resistant Prostate Cancer – Robert Dreicer
September 28, 2021
Details
STAMPEDE Analysis of Abiraterone With or Without Enzalutamide Added to Androgen Deprivation Therapy Compared to ADT Alone In High-Risk Non-Metastatic Prostate Cancer Patients– Gerhardt Attard
September 20, 2021
Details
Final Results of Phase I/II Trial of Fractionated Dose 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Scott Tagawa
September 20, 2021
Details
Combined Testosterone Therapy with Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer – Michael Schweizer
September 20, 2021
Details
Relugolix in the Phase 3 HERO Study in Men with mHSPC - Bertrand Tombal
September 19, 2021
Details
Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Karim Fizazi
September 19, 2021
Details
Health-Related Quality of Life (HRQoL) From the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer – Karim Fizazi
September 19, 2021
Details
  • About UroToday
  • Journals
  • Calendar
  • Editorial and Advertising Guidelines
  • Editors and Contributors
  • FAQs
  • Privacy Policy
  • Terms of Use
Follow UroToday

COPYRIGHT © 2002 - 2023 DIGITAL SCIENCE PRESS, LLC

Login

Login to update email address, newsletter preferences and use bookmarks.

  • Forgot Password?
  • Sign Up Free